DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity

Cellular senescence is a natural tumor suppression mechanism defined by a stable proliferation arrest. In the context of cancer treatment, cancer cell therapy-induced senescence (TIS) is emerging as an omnipresent cell fate decision that can be pharmacologically targeted at the molecular level to en...

Full description

Bibliographic Details
Published in:	Cells
Main Authors:	Nicolas Malaquin, Arthur Vancayseele, Sophie Gilbert, Laureen Antenor-Habazac, Marc-Alexandre Olivier, Zakia Ait Ali Brahem, Fred Saad, Guila Delouya, Francis Rodier
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Subjects:	prostate cancer cellular senescence senolytics PARP inhibitor enzalutamide
Online Access:	https://www.mdpi.com/2073-4409/9/7/1593

Similar Items

Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐XL–BAX interaction
by: Tareq Saleh, et al.
Published: (2020-10-01)

The Combination of Radiation with PARP Inhibition Enhances Senescence and Sensitivity to the Senolytic, Navitoclax, in Triple Negative Breast Tumor Cells
by: Abrar Softah, et al.
Published: (2023-11-01)

Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2 Japanese Subgroup Analysis
by: Nobuaki Matsubara, et al.
Published: (2025-01-01)

Sex, senescence, senolytics, and cognition
by: Thomas C. Foster, et al.
Published: (2025-03-01)

Defining melanoma combination therapies that provide senolytic sensitivity in human melanoma cells
by: Daméhan Tchelougou, et al.
Published: (2024-06-01)

Moving senolytics closer to the clinic in IPF
by: Daniel Kramer, et al.
Published: (2023-04-01)

Targeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
by: Alum EU, et al.
Published: (2025-09-01)

Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence
by: Ziqiang Fan, et al.
Published: (2024-02-01)

Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics
by: Lea Beltzig, et al.
Published: (2022-08-01)

Senolytics as drugs or fashionable dietary supplements
by: Małgorzata Starek, et al.
Published: (2021-05-01)

Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis
by: Ahmet Dirican, et al.
Published: (2022-11-01)

From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs
by: Valentin L'Hôte, et al.
Published: (2022-09-01)

The Role of Senolytics in Osteoporosis
by: Erman Chen, et al.
Published: (2025-08-01)

Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration
by: Yuhao Wu, et al.
Published: (2022-03-01)

A Review of Senolytic Drugs in Reducing the Biological Problems of Aging
by: Sara Assadiasl, et al.
Published: (2025-03-01)

Is Senolytic Therapy in Cardiovascular Diseases Ready for Translation to Clinics?
by: Zhihong Yang, et al.
Published: (2025-04-01)

Targeting Senescence: A Review of Senolytics and Senomorphics in Anti-Aging Interventions
by: Timur Saliev, et al.
Published: (2025-06-01)

Targeting Premature Renal Aging: from Molecular Mechanisms of Cellular Senescence to Senolytic Trials
by: Rossana Franzin, et al.
Published: (2021-04-01)

Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer
by: Zhe Zhu, et al.
Published: (2024-11-01)

Reduction of senescent fibro‐adipogenic progenitors in progeria‐aged muscle by senolytics rescues the function of muscle stem cells
by: Lei Liu, et al.
Published: (2022-12-01)

The senolytic agent ABT263 ameliorates osteoporosis caused by active vitamin D insufficiency through selective clearance of senescent skeletal cells
by: Cuicui Yang, et al.
Published: (2024-11-01)

Enzalutamide Sensitizes Castration‐Resistant Prostate Cancer to Copper‐Mediated Cell Death
by: Xiang Gao, et al.
Published: (2024-08-01)

Impact of senolytic treatment on immunity, aging, and disease
by: Erica C. Lorenzo, et al.
Published: (2023-10-01)

NK‐Cell‐Derived Extracellular Vesicles Engineered to Carry Senolytics Eliminate Chemotherapy‐Induced Senescent Osteosarcoma Cells
by: Xianlin Yue, et al.
Published: (2025-07-01)

Development and Application of a Senolytic Predictor for Discovery of Novel Senolytic Compounds and Herbs
by: Jinjun Li, et al.
Published: (2025-06-01)

Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice
by: Edward Fielder, et al.
Published: (2022-05-01)

EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263
by: Ibrahim Y. Abdelgawad, et al.
Published: (2022-06-01)

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer
by: Nair Lopes, et al.
Published: (2021-08-01)

Senolytic effect of triterpenoid complex from Ganoderma lucidum on adriamycin-induced senescent human hepatocellular carcinoma cells model in vitro and in vivo
by: Ahmed Attia Ahmed Abdelmoaty, et al.
Published: (2024-09-01)

Outcomes Management in a Real-World Evidence Context: The Case of Abiraterone and Enzalutamide in the Treatment of Metastatic Castration-Resistant Prostate Cancer
by: Pedro Cardoso, et al.
Published: (2020-05-01)

Chemoinformatic Screening for the Selection of Potential Senolytic Compounds from Natural Products
by: Oscar Salvador Barrera-Vázquez, et al.
Published: (2021-03-01)

Enzalutamide Maintenance Following Docetaxel in Metastatic Castration-Naive Prostate Cancer: A Pilot Feasibility Study
by: Sung Hee Lim, et al.
Published: (2024-03-01)

THE PLACE OF ENZALUTAMIDE IN THE SERIAL TREATMENT OF TREATMENT-RESISTANT PROSTATE CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Failure of senolytic treatment to prevent cognitive decline in a female rodent model of aging
by: Asha Rani, et al.
Published: (2024-05-01)

Senolytic treatment with dasatinib and quercetin does not improve overall influenza responses in aged mice
by: Blake L. Torrance, et al.
Published: (2023-06-01)

Rationale and design of STAMINA: Senolytics to alleviate mobility issues and neurological impairments in aging, a geroscience feasibility study
by: Courtney L. Millar, et al.
Published: (2023-01-01)

Senolytic Cocktail Dasatinib+Quercetin (D+Q) Does Not Enhance the Efficacy of Senescence-Inducing Chemotherapy in Liver Cancer
by: Kristina Kovacovicova, et al.
Published: (2018-10-01)

Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer
by: Zhu Wen, et al.
Published: (2024-08-01)

Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events
by: Aswini Kumar, et al.
Published: (2023-01-01)

Integrated bioinformatics analysis reveals that OPRK1 inhibits ferroptosis and induces enzalutamide resistance in prostate cancer
by: Liangrong Zhang, et al.
Published: (2025-04-01)